Non-saturated, accurate binding surface orientation
Blocked with hydrophilic copolymer and coupled with biotinylated BSA which:
- Properly orients capture antibody
- Prevents surface crowding and ligand inactivation through non-specific binding
- Enhances dispersion of particles
- Improves binding efficiency
MagBead Protocol
MagBead Activation
Immunocapture
Rituximab Signature Peptide — ASGYTFTSYNMHWVK
Comparison of Dynabeads M-280 vs. Biozen MagBeads
|
Column:
Biozen 3 µm Peptide PS-C18
|
|
Dimension:
50 x 2.1 mm
|
|
Part No.:
00B-4771-AN
|
|
Mobile Phase:
A: 0.1 % Formic acid in Water B: 0.1 % Formic acid in Acetonitrile
|
|
Gradient:
3-50 % B in 4.5 minutes
|
|
Flow Rate:
0.3 mL/min
|
|
Temperature:
40 °C
|
|
Detection:
SCIEX X500B Q-TOF
|
|
Sample:
Rituximab 1.5 µg/mL (ASGYTFTSYNMHWVK)
|
Biozen MagBeads Binding Activity Leads to Accurate and Sensitive Results
Rituximab
- Reduction in non-specific binding
- Excellent reproducibility lot-to-lot
| Immunocapture Bead | Correlation Coefficient |
|---|---|
| Thermo® Dynabeads M-280 | 0.9176 |
| Biozen MagBeads, Lot 1 | 0.9914 |
| Biozen MagBeads, Lot 2 | 0.9941 |
Comparative separations may not be representative of all applications.
Troponin
- Increased assay precision
- Improvements in response






























